Abstract 16384: Longitudinal Assessment of Plaque Inflammation on Statin Therapy Evaluated by 18F-FDG PET/CT: a Prospective Interventional Study
Background: Statin has shown robust plaque-stabilizing effect mainly by reducing plasma LDL-cholesterol (LDL-C) levels. Longitudinal alterations in plaque inflammation during a year of statin therapy have never been imaged, tracked, and quantified in humans. Thus, this study aims to image the alterations in the quantity of plaque inflammation induced by statin therapy by using serial 18F-FDG PET/CT and correlate to changes in plasma LDL-C levels.
Methods: This is a prospective, interventional study in statin-naïve, stable angina patients with carotid plaques. After obtaining initial 18F- FDG PET/CT of carotid arteries, 40 patients received atorvastatin 20mg/day, followed by a second (n=28; at 3 months) and a third FDG PET/CT (n=9; at 1 year). Primary observational endpoint was the percent change in arterial wall inflammation from baseline to second and second to third FDG PET/CT assessed by the difference in target-to-background ratio (Δ TBR) within the index carotid artery.
Results: Atorvastatin reduced mean LDL-C level by 36.4% within 3months (p=0.001) and the level did not reduce further for the next 9 months (p=0.516). The percentage change of Δ TBR in the index vessel showed continued reduction in plaque inflammation over 1 year of statin therapy: from baseline to 3 months; 4.4% (p=0.015) and 3 months to 1 year; 6.2% (p=0.009).
Conclusions: This study demonstrates that statin continuously reduces plaque inflammation on carotid atherosclerosis until 1 year even after achieving a stable below-target plasma LDL-C level at 3 months.
- © 2013 by American Heart Association, Inc.